Pseudomonas aeruginosa biofilms and the capacity of the bacterium to coexist and interact
with a broad range of microorganisms have a substantial clinical impact. This review focuses …

Pulmonary drug delivery is a highly attractive topic for the treatment of infectious lung
diseases. Drug delivery via the pulmonary route offers unique advantages of no first-pass …

Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated
antiviral activity against a number of DNA and RNA viruses, including severe acute …

Clinical therapy of multidrug resistant (MDR) bacteria‐induced deep‐tissue infections such
as pneumonia is highly challenging. Ultrasound (US)‐induced sonodynamic therapy (SDT) …

The rise in the resistance to antibiotics is due to their inappropriate use and the use of a
broad spectrum of antibiotics. This has also contributed to the development of multidrug …

Respiratory disorders are among the most important medical problems threatening human
life. The conventional therapeutics for respiratory disorders are hindered by insufficient drug …

Polymyxins are vital antibiotics for the treatment of multiresistant Gram-negative ESKAPE
pathogen infections. However, their clinical value is limited by their high nephrotoxicity and …

This study aims to prepare hybrid chitosan-alginate aerogel microparticles without using
additional ionic crosslinker as a possible pulmonary drug delivery system. The …

Pulmonary delivery is an alternative route of administration with numerous advantages over
conventional routes of administration. It provides low enzymatic exposure, fewer systemic …

Delivery of medications to preterm neonates receiving non-invasive ventilation (NIV)
represents one of the most challenging scenarios for aerosol medicine. This challenge is …